cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.1285067
title: Data for vitD - PTH paper

description: Data for all the figures in the manuscript: PLOS ONE: PONE-D-14-33969R1 - [EMID:a23075f29839dd31]
DOI: 10.6084/m9.figshare.1285069.v1
title: Data storage & retention. Training materials RDM Support basic training course for information specialists session 3

description: Training materials for 'Data storage & retention', session 3 of the RDM Support basic training course for information specialists. RDM Support is a basic training course in research data management (support) for information specialists. The training course was developed by Mariëtte van Selm for the information specialists of the Library of the University of Amsterdam (UvA), within the framework of the RDM Support project (2013-2015). The training course was held from January to April 2014.
DOI: 10.6084/m9.figshare.1285066
title: Research data management: an introduction. Training materials RDM Support basic training course for information specialists session 1

description: Training materials for 'Research Data Management: an introduction', session 1 of the RDM Support basic training course for information specialists. RDM Support is a basic training course in research data management (support) for information specialists. The training course was developed by Mariëtte van Selm for the information specialists of the Library of the University of Amsterdam (UvA), within the framework of the RDM Support project (2013-2015). The training course was held from January to April 2014.
DOI: 10.6084/m9.figshare.1285067.v1
title: Data for vitD - PTH paper

description: Data for all the figures in the manuscript: PLOS ONE: PONE-D-14-33969R1 - [EMID:a23075f29839dd31]
DOI: 10.6084/m9.figshare.1285068
title: Data management planning. Training materials RDM Support basic training course for information specialists session 2

description: Training materials for 'Data management planning', session 2 of the RDM Support basic training course for information specialists. RDM Support is a basic training course in research data management (support) for information specialists. The training course was developed by Mariëtte van Selm for the information specialists of the Library of the University of Amsterdam (UvA), within the framework of the RDM Support project (2013-2015). The training course was held from January to April 2014.
DOI: 10.6084/m9.figshare.1285066.v1
title: Research data management: an introduction. Training materials RDM Support basic training course for information specialists session 1

description: Training materials for 'Research Data Management: an introduction', session 1 of the RDM Support basic training course for information specialists. RDM Support is a basic training course in research data management (support) for information specialists. The training course was developed by Mariëtte van Selm for the information specialists of the Library of the University of Amsterdam (UvA), within the framework of the RDM Support project (2013-2015). The training course was held from January to April 2014.
DOI: 10.6084/m9.figshare.1285068.v1
title: Data management planning. Training materials RDM Support basic training course for information specialists session 2

description: Training materials for 'Data management planning', session 2 of the RDM Support basic training course for information specialists. RDM Support is a basic training course in research data management (support) for information specialists. The training course was developed by Mariëtte van Selm for the information specialists of the Library of the University of Amsterdam (UvA), within the framework of the RDM Support project (2013-2015). The training course was held from January to April 2014.
DOI: 10.6084/m9.figshare.1285032
title: Wychowanie w Rodzinie / Family Upbringing // Przekaz tradycji i kultury na przestrzeni wieków / The transferring of culture and tradition throughout centuries

description: Journal: "Wychowanie w Rodzinie" / "Family Upbringing", Volume I (1/2011). S. Walasek & L. Albański (Eds.) Chief Editor: Stefania Walasek Second Chief Editor: Ewa Jurczyk-Romanowska (since 2013) Secretary of the Editorial Board: Ewa Jurczyk-Romanowska (till 2013) Chief Editor: Stefania Walasek<br>Second Chief Editor: Ewa Jurczyk-Romanowska (since 2013)<br>Secretary of the Editorial Board: Ewa Jurczyk-Romanowska (till 2013)<br>ISSN:2082-9019<br>e-ISSN: 2300-5866<br>www.wwr.uni.wroc.pl
DOI: 10.6084/m9.figshare.1285032.v1
title: Wychowanie w Rodzinie / Family Upbringing // Przekaz tradycji i kultury na przestrzeni wieków / The transferring of culture and tradition throughout centuries

description: Journal: "Wychowanie w Rodzinie" / "Family Upbringing", Volume I (1/2011). S. Walasek & L. Albański (Eds.) Chief Editor: Stefania Walasek Second Chief Editor: Ewa Jurczyk-Romanowska (since 2013) Secretary of the Editorial Board: Ewa Jurczyk-Romanowska (till 2013) Chief Editor: Stefania Walasek<br>Second Chief Editor: Ewa Jurczyk-Romanowska (since 2013)<br>Secretary of the Editorial Board: Ewa Jurczyk-Romanowska (till 2013)<br>ISSN:2082-9019<br>e-ISSN: 2300-5866<br>www.wwr.uni.wroc.pl
DOI: 10.6084/m9.figshare.1285024
title: The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer

description: A phase Ib/II trial was performed to evaluate safety, tolerability, recommended dose (RD) and efficacy of F16-IL2, a recombinant antibody-cytokine fusion protein, in combination with doxorubicin in patients with solid tumors (phase Ib) and metastatic breast cancer (phase II). Six patient cohorts with progressive solid tumors (n = 19) received escalating doses of F16-IL2 [5–25 Million International Units (MIU) of IL2 equivalent dose] in combination with escalating doses of doxorubicin (0–25 mg/m<sup>2</sup>) on day 1, 8 and 15 every 4 weeks. Subsequently, patients with metastatic breast cancer (n = 10) received the drug combination at the RD. Clinical data and laboratory findings were analyzed for safety, tolerability, and activity. F16-IL2 could be administered up to 25 MIU, in combination with the RD of doxorubicin (25 mg/m<sup>2</sup>). No human anti-fusion protein antibodies (HAFA) response was detected. Pharmacokinetics of F16-IL2 was dose-dependent over the tested range, with half-lives of ca. 13 and ca. 8 hours for cohorts dosed at lower and higher levels, respectively. Toxicities were controllable and reversible, with no combination treatment-related death. After 8 weeks, 57% and 67% disease control rates were observed for Phase I and II, respectively (decreasing to 43% and 33% after 12 weeks), considering 14 and 9 patients evaluable for efficacy. One patient experienced a long lasting partial response (45 weeks), still on-going at exit of study. F16-IL2 can be safely and repeatedly administered at the RD of 25 MIU in combination with 25 mg/m<sup>2</sup> doxorubicin; its safety and activity are currently being investigated in combination with other chemotherapeutics, in order to establish optimal therapy settings.
DOI: 10.6084/m9.figshare.1285024.v1
title: The tumour-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumours and expansion into patients with metastatic breast cancer

description: .A phase Ib/II trial was performed to evaluate safety, tolerability, recommended dose (RD) and efficacy of F16-IL2, a recombinant antibody-cytokine fusion protein, in combination with doxorubicin in patients with solid tumours (phase Ib) and metastatic breast cancer (phase II).Six patient cohorts with progressive solid tumours (n = 19) received escalating doses of F16-IL2 [5-25 Million International Units (MIU) of IL2 equivalent dose] in combination with escalating doses of doxorubicin (0-25mg/m<sup>2</sup>) on day 1, 8 and 15 every 4 weeks. Subsequently, patients with metastatic breast cancer (n = 10) received the drug combination at the RD. Clinical data and laboratory findings were analysed for safety, tolerability, and activity.F16-IL2 could be administered up to 25 MIU, in combination with the RD of doxorubicin (25mg/m<sup>2</sup>). No human anti-fusion protein antibodies (HAFA) response was detected. Pharmacokinetics of F16-IL2 was dose-dependent over the tested range, with half-lives of ca. 13 and ca. 8 hours for cohorts dosed at lower and higher levels, respectively.Toxicities were controllable and reversible, with no combination treatment-related death. After 8 weeks, 57% and 67% disease control rates were observed for Phase I and II, respectively (decreasing to 43% and 33% after 12 weeks), considering 14 and 9 patients evaluable for efficacy. One patient experienced a long lasting partial response (45 weeks), still on-going at exit of study.F16-IL2 can be safely and repeatedly administered at the RD of 25 Mio I.U. in combination with 25mg/m<sup>2</sup> doxorubicin; its safety and activity are currently being investigated in combination with other chemotherapeutics, in order to establish optimal therapy settings.
DOI: 10.6084/m9.figshare.1285017
title: Autophagy contributes to regulation of nuclear dynamics during vegetative growth and hyphal fusion in <i>Fusarium oxysporum</i>

description: In the fungal pathogen <i>Fusarium oxysporum</i>, vegetative hyphal fusion triggers nuclear mitotic division in the invading hypha followed by migration of a nucleus into the receptor hypha and degradation of the resident nucleus. Here we examined the role of autophagy in fusion-induced nuclear degradation. A search of the <i>F. oxysporum</i> genome database for autophagy pathway components identified putative orthologs of 16 core autophagy-related (<i>ATG</i>) genes in yeast, including the ubiquitin-like protein Atg8, which is required for the formation of autophagosomal membranes. <i>F. oxysporum Foatg8</i>Δ mutants were generated in a strain harboring H1-cherry fluorescent protein (ChFP)-labeled nuclei to facilitate analysis of nuclear dynamics. The <i>Foatg8</i>Δ mutants did not show MDC-positive staining in contrast to the wild type and the <i>FoATG8</i>-complemented (c<i>FoATG8</i>) strain, suggesting that FoAtg8 is required for autophagy in <i>F. oxysporum</i>. The <i>Foatg8</i>Δ strains displayed reduced rates of hyphal growth, conidiation, and fusion, and were significantly attenuated in virulence on tomato plants and in the nonvertebrate animal host <i>Galleria mellonella</i>. In contrast to wild-type hyphae, which are almost exclusively composed of uninucleated hyphal compartments, the hyphae of the <i>Foatg8</i>Δ mutants contained a significant fraction of hyphal compartments with 2 or more nuclei. The increase in the number of nuclei per hyphal compartment was particularly evident after hyphal fusion events. Time-lapse microscopy analyses revealed abnormal mitotic patterns during vegetative growth in the <i>Foatg8</i>Δ mutants. Our results suggest that autophagy mediates nuclear degradation after hyphal fusion and has a general function in the control of nuclear distribution in <i>F. oxysporum</i>.
DOI: 10.6084/m9.figshare.1285016
title: Synthesis and Crystal Structure of Triethylammonium 2,4,14,16-Tetrachlorodibenzo[g,j][1,3,6,12]Tetraoxacyclo-Tetradecane-2-Phosphorodithioate

description: GRAPHICAL ABSTRACT
DOI: 10.6084/m9.figshare.1285024.v2
title: The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer

description: A phase Ib/II trial was performed to evaluate safety, tolerability, recommended dose (RD) and efficacy of F16-IL2, a recombinant antibody-cytokine fusion protein, in combination with doxorubicin in patients with solid tumors (phase Ib) and metastatic breast cancer (phase II). Six patient cohorts with progressive solid tumors (n = 19) received escalating doses of F16-IL2 [5–25 Million International Units (MIU) of IL2 equivalent dose] in combination with escalating doses of doxorubicin (0–25 mg/m<sup>2</sup>) on day 1, 8 and 15 every 4 weeks. Subsequently, patients with metastatic breast cancer (n = 10) received the drug combination at the RD. Clinical data and laboratory findings were analyzed for safety, tolerability, and activity. F16-IL2 could be administered up to 25 MIU, in combination with the RD of doxorubicin (25 mg/m<sup>2</sup>). No human anti-fusion protein antibodies (HAFA) response was detected. Pharmacokinetics of F16-IL2 was dose-dependent over the tested range, with half-lives of ca. 13 and ca. 8 hours for cohorts dosed at lower and higher levels, respectively. Toxicities were controllable and reversible, with no combination treatment-related death. After 8 weeks, 57% and 67% disease control rates were observed for Phase I and II, respectively (decreasing to 43% and 33% after 12 weeks), considering 14 and 9 patients evaluable for efficacy. One patient experienced a long lasting partial response (45 weeks), still on-going at exit of study. F16-IL2 can be safely and repeatedly administered at the RD of 25 MIU in combination with 25 mg/m<sup>2</sup> doxorubicin; its safety and activity are currently being investigated in combination with other chemotherapeutics, in order to establish optimal therapy settings.
DOI: 10.6084/m9.figshare.1285017.v2
title: Autophagy contributes to regulation of nuclear dynamics during vegetative growth and hyphal fusion in <i>Fusarium oxysporum</i>

description: In the fungal pathogen <i>Fusarium oxysporum</i>, vegetative hyphal fusion triggers nuclear mitotic division in the invading hypha followed by migration of a nucleus into the receptor hypha and degradation of the resident nucleus. Here we examined the role of autophagy in fusion-induced nuclear degradation. A search of the <i>F. oxysporum</i> genome database for autophagy pathway components identified putative orthologs of 16 core autophagy-related (<i>ATG</i>) genes in yeast, including the ubiquitin-like protein Atg8, which is required for the formation of autophagosomal membranes. <i>F. oxysporum Foatg8</i>Δ mutants were generated in a strain harboring H1-cherry fluorescent protein (ChFP)-labeled nuclei to facilitate analysis of nuclear dynamics. The <i>Foatg8</i>Δ mutants did not show MDC-positive staining in contrast to the wild type and the <i>FoATG8</i>-complemented (c<i>FoATG8</i>) strain, suggesting that FoAtg8 is required for autophagy in <i>F. oxysporum</i>. The <i>Foatg8</i>Δ strains displayed reduced rates of hyphal growth, conidiation, and fusion, and were significantly attenuated in virulence on tomato plants and in the nonvertebrate animal host <i>Galleria mellonella</i>. In contrast to wild-type hyphae, which are almost exclusively composed of uninucleated hyphal compartments, the hyphae of the <i>Foatg8</i>Δ mutants contained a significant fraction of hyphal compartments with 2 or more nuclei. The increase in the number of nuclei per hyphal compartment was particularly evident after hyphal fusion events. Time-lapse microscopy analyses revealed abnormal mitotic patterns during vegetative growth in the <i>Foatg8</i>Δ mutants. Our results suggest that autophagy mediates nuclear degradation after hyphal fusion and has a general function in the control of nuclear distribution in <i>F. oxysporum</i>.
DOI: 10.6084/m9.figshare.1285024.v3
title: The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer

description: A phase Ib/II trial was performed to evaluate safety, tolerability, recommended dose (RD) and efficacy of F16-IL2, a recombinant antibody-cytokine fusion protein, in combination with doxorubicin in patients with solid tumors (phase Ib) and metastatic breast cancer (phase II). Six patient cohorts with progressive solid tumors (n = 19) received escalating doses of F16-IL2 [5–25 Million International Units (MIU) of IL2 equivalent dose] in combination with escalating doses of doxorubicin (0–25 mg/m<sup>2</sup>) on day 1, 8 and 15 every 4 weeks. Subsequently, patients with metastatic breast cancer (n = 10) received the drug combination at the RD. Clinical data and laboratory findings were analyzed for safety, tolerability, and activity. F16-IL2 could be administered up to 25 MIU, in combination with the RD of doxorubicin (25 mg/m<sup>2</sup>). No human anti-fusion protein antibodies (HAFA) response was detected. Pharmacokinetics of F16-IL2 was dose-dependent over the tested range, with half-lives of ca. 13 and ca. 8 hours for cohorts dosed at lower and higher levels, respectively. Toxicities were controllable and reversible, with no combination treatment-related death. After 8 weeks, 57% and 67% disease control rates were observed for Phase I and II, respectively (decreasing to 43% and 33% after 12 weeks), considering 14 and 9 patients evaluable for efficacy. One patient experienced a long lasting partial response (45 weeks), still on-going at exit of study. F16-IL2 can be safely and repeatedly administered at the RD of 25 MIU in combination with 25 mg/m<sup>2</sup> doxorubicin; its safety and activity are currently being investigated in combination with other chemotherapeutics, in order to establish optimal therapy settings.
DOI: 10.6084/m9.figshare.1285016.v2
title: Synthesis and Crystal Structure of Triethylammonium 2,4,14,16-Tetrachlorodibenzo[g,j][1,3,6,12]Tetraoxacyclo-Tetradecane-2-Phosphorodithioate

description: GRAPHICAL ABSTRACT
DOI: 10.6084/m9.figshare.1285017.v1
title: Autophagy contributes to regulation of nuclear dynamics during vegetative growth and hyphal fusion in Fusarium oxysporum

description: In the fungal pathogen <i>Fusarium oxysporum</i>, vegetative hyphal fusion triggers nuclear mitotic division in the invading hypha followed by migration of a nucleus into the receptor hypha and degradation of the resident nucleus. Here we examined the role of autophagy in fusion-induced nuclear degradation. A search of the <i>F. oxysporum</i> genome database for autophagy pathway components identified putative orthologs of 16 core autophagy-related (<i>ATG</i>) genes in yeast, including the ubiquitin-like protein Atg8, which is required for the formation of autophagosomal membranes. <i>F. oxysporum Foatg8</i>Δ mutants were generated in a strain harboring H1-cherry fluorescent protein (ChFP)-labeled nuclei to facilitate analysis of nuclear dynamics. The <i>Foatg8</i>Δ mutants did not show MDC-positive staining in contrast to the wild type and the <i>FoATG8</i>-complemented (c<i>FoATG8</i>) strain, suggesting that FoAtg8 is required for autophagy in <i>F. oxysporum</i>. The <i>Foatg8</i>Δ strains displayed reduced rates of hyphal growth, conidiation, and fusion, and were significantly attenuated in virulence on tomato plants and in the nonvertebrate animal host <i>Galleria mellonella</i>. In contrast to wild-type hyphae, which are almost exclusively composed of uninucleated hyphal compartments, the hyphae of the <i>Foatg8</i>Δ mutants contained a significant fraction of hyphal compartments with 2 or more nuclei. The increase in the number of nuclei per hyphal compartment was particularly evident after hyphal fusion events. Time-lapse microscopy analyses revealed abnormal mitotic patterns during vegetative growth in the <i>Foatg8</i>Δ mutants. Our results suggest that autophagy mediates nuclear degradation after hyphal fusion and has a general function in the control of nuclear distribution in <i>F. oxysporum</i>.
DOI: 10.6084/m9.figshare.1285024.v5
title: The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer

description: A phase Ib/II trial was performed to evaluate safety, tolerability, recommended dose (RD) and efficacy of F16-IL2, a recombinant antibody-cytokine fusion protein, in combination with doxorubicin in patients with solid tumors (phase Ib) and metastatic breast cancer (phase II). Six patient cohorts with progressive solid tumors (n = 19) received escalating doses of F16-IL2 [5–25 Million International Units (MIU) of IL2 equivalent dose] in combination with escalating doses of doxorubicin (0–25 mg/m<sup>2</sup>) on day 1, 8 and 15 every 4 weeks. Subsequently, patients with metastatic breast cancer (n = 10) received the drug combination at the RD. Clinical data and laboratory findings were analyzed for safety, tolerability, and activity. F16-IL2 could be administered up to 25 MIU, in combination with the RD of doxorubicin (25 mg/m<sup>2</sup>). No human anti-fusion protein antibodies (HAFA) response was detected. Pharmacokinetics of F16-IL2 was dose-dependent over the tested range, with half-lives of ca. 13 and ca. 8 hours for cohorts dosed at lower and higher levels, respectively. Toxicities were controllable and reversible, with no combination treatment-related death. After 8 weeks, 57% and 67% disease control rates were observed for Phase I and II, respectively (decreasing to 43% and 33% after 12 weeks), considering 14 and 9 patients evaluable for efficacy. One patient experienced a long lasting partial response (45 weeks), still on-going at exit of study. F16-IL2 can be safely and repeatedly administered at the RD of 25 MIU in combination with 25 mg/m<sup>2</sup> doxorubicin; its safety and activity are currently being investigated in combination with other chemotherapeutics, in order to establish optimal therapy settings.
DOI: 10.6084/m9.figshare.1285016.v1
title: Synthesis and Crystal Structure of Triethylammonium 2,4,14,16-Tetrachlorodibenzo[g,j][1,3,6,12]Tetraoxacyclo-Tetradecane-2-Phosphorodithioate

description: GRAPHICAL ABSTRACT
DOI: 10.6084/m9.figshare.1285024.v4
title: The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer

description: A phase Ib/II trial was performed to evaluate safety, tolerability, recommended dose (RD) and efficacy of F16-IL2, a recombinant antibody-cytokine fusion protein, in combination with doxorubicin in patients with solid tumors (phase Ib) and metastatic breast cancer (phase II). Six patient cohorts with progressive solid tumors (n = 19) received escalating doses of F16-IL2 [5–25 Million International Units (MIU) of IL2 equivalent dose] in combination with escalating doses of doxorubicin (0–25 mg/m<sup>2</sup>) on day 1, 8 and 15 every 4 weeks. Subsequently, patients with metastatic breast cancer (n = 10) received the drug combination at the RD. Clinical data and laboratory findings were analyzed for safety, tolerability, and activity. F16-IL2 could be administered up to 25 MIU, in combination with the RD of doxorubicin (25 mg/m<sup>2</sup>). No human anti-fusion protein antibodies (HAFA) response was detected. Pharmacokinetics of F16-IL2 was dose-dependent over the tested range, with half-lives of ca. 13 and ca. 8 hours for cohorts dosed at lower and higher levels, respectively. Toxicities were controllable and reversible, with no combination treatment-related death. After 8 weeks, 57% and 67% disease control rates were observed for Phase I and II, respectively (decreasing to 43% and 33% after 12 weeks), considering 14 and 9 patients evaluable for efficacy. One patient experienced a long lasting partial response (45 weeks), still on-going at exit of study. F16-IL2 can be safely and repeatedly administered at the RD of 25 MIU in combination with 25 mg/m<sup>2</sup> doxorubicin; its safety and activity are currently being investigated in combination with other chemotherapeutics, in order to establish optimal therapy settings.
DOI: 10.6084/m9.figshare.1285007
title: Analysis scripts for MM gene signature combination

description: Full analysis scripts for MM gene signature combination study. Please refer to the README first for the proper order of analysis for reproduction.
DOI: 10.6084/m9.figshare.1285007.v1
title: Analysis scripts for MM gene signature combination

description: Full analysis scripts for MM gene signature combination study. Please refer to the README first for the proper order of analysis for reproduction.